title: The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
authors.affiliation: College of Public Health, University of Nebraska Medical Center, 984395 Nebraska Medical Center, Omaha, NE 68198-4395, USA. janderson@unmc.edu
authors.forename: James R
authors.initials: JR
authors.lastname: Anderson
authors.forename: Mark
authors.initials: M
authors.lastname: Krailo
mesh_terms: D004999:Amifostine / Q000627:therapeutic use; D002648:Child; D026661:Clinical Trials Data Monitoring Committees; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000592:standards*; D057239:Early Termination of Clinical Trials; D018197:Hepatoblastoma / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards*; D012107:Research Design / Q000592:standards*; D012206:Rhabdomyolysis / Q000139:chemically induced; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011837:Radiation-Protective Agents; D004999:Amifostine